Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651Robert I. Haddad, Athanassios Argiris, Maura L. Gillison et al.|Journal of Clinical Oncology|2022Cited by 159
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckKevin J. Harrington, Robert I. Haddad, Robert L. Ferris et al.|JAMA Oncology|2023Cited by 73